VDVirgil Alain Silvester Hovestadt Dalm

Virgil Alain Silvester Hovestadt Dalm

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Virgil Alain Silvester Hovestadt Dalm has a total of 340 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Open-label extension study of leniolisib in activated PI3Kδ syndrome: Long-term efficacy and safety

    by V. Koneti Rao, Anna Šedivá, Virgil A.S.H. Dalm, Alessandro Plebani, Catharina Schuetz, Anna Shcherbina, Antonio Trizzino, Yulia Zharankova, Alanvin Orpia, Elaine Kulm, et al.

    Activated phosphoinositide 3-kinase delta syndrome (APDS) is an inborn error of immunity characterized by immune deficiency and dysregulation. Leniolisib is a selective phosphoinositide 3-kinase delta inhibitor approved to treat APDS in patients ≥12 years old. We report final results from a single-arm, open-label extension study in 37 patients with APDS (NCT02859727). Median leniolisib exposure was 4.3 years (range, 1.2–7.0 years). Adverse events (AE) were reported in 34 patients; 87% were grade 1. Serious AEs, reported in 10 patients, were deemed unrelated to leniolisib. Two patients discontinued treatment due to AEs: cardiac arrest and Hodgkin’s lymphoma. There were significant reductions in annual infection (P = 0.0005) and respiratory infection (P = 0.0017) rates per year of treatment. Immunoglobulin replacement therapy (IRT) use significantly decreased per year of treatment (P = 0.0095). Clinically meaningful improvements in general health scores from the 36-Item Short Form Survey were observed. Overall, long-term use of leniolisib was generally well tolerated, and infections and IRT use reduced over time.

  • Open Access

    Population Pharmacokinetics and Pharmacodynamics of Immunoglobulins: A Systematic Review

    by S. L. van der Zeeuw, S. J. van Tilburg, B. C. Jacobs, B. C. P. Koch, V. A. S. H. Dalm, M. B. S. Crombag, T. Preijers

    Background and Objective Intravenous and/or subcutaneous immunoglobulins (IVIg/SCIg) are used as immunoglobulin replacement therapy (IgRT) in primary and secondary immunodeficiencies (PID/SID) and as immunomodulatory therapy in immune-mediated diseases. Despite empiric immunoglobulin G (IgG) target concentrations in PID, dosing remains variable and suboptimal, particularly in immune-mediated diseases lacking clear IgG target concentrations. Population pharmacokinetic (popPK) and pharmacodynamic (PD) modelling may clarify interindividual variability and support individualised dosing. Recent developments extend beyond PID, emphasising the importance of integrated PK-PD approaches to optimise IgG therapy. This review aimed to provide a comprehensive overview of popPK(-PD) models describing polyclonal IgG therapy, and to emphasise the added value of PK-PD in understanding drug behaviour. Methods A systematic literature search was conducted in Embase, MEDLINE, and Web of Science from inception to August 2025. Studies describing popPK(-PD) models for exogenous polyclonal IVIg and/or SCIg administration in humans were included. Results In total, 14 studies were included. While most popPK models focus on PID (N = 10), an increasing number address immune-mediated diseases. Immunoglobulin G pharmacokinetics are typically described using two-compartment models with first-order kinetics, using body weight (BW) as a common covariate for clearance and volume of distribution. Endogenous IgG is often incorporated as a fixed PK parameter; however, this may not adequately capture interindividual variability and potential effects of Ig treatment on IgG concentrations. Two popPK-PD models link IgG concentrations to clinical outcomes in immune-mediated diseases. In contrast, such models are currently lacking for PID. Simulations showed consistent predicted IgG concentrations following SCIg in PID, while IVIg models in PID showed more variability. Conclusions PopPK models have advanced understanding of IgG PK and its variability between patients and treatment regimens. These models provide a powerful framework to support individualised dosing strategies, thereby potentially reducing reliance on empirical, trial-and-error dosing approaches. However, clear target concentrations are lacking and must be established for individual patients. Models may be further optimised by incorporating essential Neonatal Fc receptor (FcRn) mechanisms using physiology-based pharmacokinetic (PBPK) or semi-mechanistic models. In conclusion, current models are useful to predict IgG concentrations across diseases during Ig treatment; however, a clearer relationship with PD is required. Hence, these findings can guide clinical trial design for tailored dosing regimens. Graphical abstract The alternative text for this image may have been generated using AI.


  • Open Access

    Determinants of pro- and anti-inflammatory cytokine profiles across populations

    by Samantha E. Leonard, Mohsen Ghanbari, Pawel Sowa, Joyce B.J. van Meurs, Costanza Vallerga, P. Martin van Hagen, Henry Völzke, Sabine Ameling, Uwe Völker, Marcin Kondraciuk, et al.

    Cytokine dysregulation contributes to chronic inflammation and immune-mediated diseases, yet population-level determinants of pro- and anti-inflammatory cy

  • Open Access

    Immune Signatures of Smoking: Cytokine and Immunoglobulin Dysregulation and Partial Reversibility in a Population-Based Study

    by Samantha E. Leonard, Mohsen Ghanbari, Lies Lahousse, Joyce B. J. van Meurs, P. Martin van Hagen, Layal Chaker, Virgil A. S. H. Dalm

    While smoking-induced epigenetic changes are increasingly recognized, the relationship between varying smoking history and immune protein profiles remains incompletely understood. This study investigates associations between smoking history and circulating inflammatory cytokines and serum immunoglobulins, and explores DNA methylation as a potential mediator. We analyzed 2,119 participants from the Rotterdam Study, examining associations of smoking duration, pack-years, and cessation time with plasma inflammatory proteins, including six pro- and three anti-inflammatory cytokines (Olink) and three serum immunoglobulins (IgA, IgG, and IgM). Cytokines were z-transformed and multivariable (non)linear regression models were applied, adjusted for age, sex, BMI, alcohol use, and socioeconomic status. A distinct immune signature emerged, with (z-transformed) IL-6, IL-18, IL-17C, and IL-10 levels increasing with pack-years and smoking duration (β range: 0.0029 to 0.015). IgA and IgG displayed reverse J-shaped associations with pack-years (β range: –0.050 to 0.048) and levels declined with smoking duration (β = –0.0067 and –0.028, respectively). IL-6, IL-17A, and IL-10 decreased with cessation time (β range: -0.007 to -0.004), and IgG increased (β = 0.018). IgM responses differed by sex. Mediation analysis using PCA-derived CpG components did not support a role for DNA methylation in these associations. These findings reveal dose-dependent, pro-inflammatory immune dysregulation with cumulative smoking exposure and partial reversibility of IL-6 and IgG following cessation. The absence of mediation by DNA methylation suggests other pathways are involved. These findings support the use of cytokines and immunoglobulins as biomarkers for immune surveillance and recovery monitoring, reflecting an underlying inflammatory smoking signature.

  • Open Access

    Increasing inflammatory biomarkers are associated with mortality in critically ill COVID-19 patients despite anti-inflammatory treatment

    by Katrijn Daenen, Dimitris Rizopoulos, Virgil A. S. H. Dalm, Jilske A. Huijben, Sara C. M. Stoof, Nicole M. A. Nagtzaam, Willem A. Dik, Sigrid M. A. Swagemakers, Peter J. van der Spek, Kirby Tong-Minh, et al.

    Predicting mortality in COVID-19 ARDS may support ICU clinical decision-making. Biomarkers of innate immunity, coagulation, endothelial injury, and fibroproliferation have been studied as predictors. We aimed to examine whether trends in plasma biomarkers predict ICU mortality and to explore underlying biological processes through pathway analysis. Additionally, we explored whether HDS changes biomarker trajectories in COVID-19 ARDS. In this observational study, we included patients with COVID-19 ARDS admitted to the ICU of an academic hospital in Rotterdam between February 2020 and February 2022. In repeated plasma samples, 64 biomarkers were measured. Joint modeling assessed the association between biomarker changes and ICU mortality, adjusting for age, sex, BMI, and HDS. Protein–protein interaction and gene ontology enrichment analyses were performed using STRING, Cytoscape, and DAVID EASE. Biomarker trajectories were compared between HDS-treated and non-treated patients, adjusting for timing, SOFA score, and tocilizumab. One hundred and sixty-two patients were included and 43 died during ICU stay. A doubling in the values of 26 biomarkers over the next day was predictive of ICU mortality (HRs 0.16–8.56; q < 0.05). Gene ontology enrichment analysis identified 19 overrepresented biological processes (FDR ≤ 0.05), with highest fold enrichment for macrophage chemotaxis, negative regulation of bone resorption, and leukocyte cell–cell adhesion. Forty-eight patients received HDS at a median of 6 ICU days. HDS significantly changed the trajectories of four mortality-associated biomarkers: Albumin and lactoferrin decreased, while CRP and VEGF increased. In COVID-19 ARDS, repeated biomarker measurements demonstrate a systemic inflammatory state associated with mortality. HDS changed trends of several biomarkers, but did not reduce those associated with fatal outcomes. Trial registration : ClinicalTrials.gov NCT05403359; https://clinicaltrials.gov/ct2/show/NCT05403359


  • Open Access

    Interstitial 11q Deletions and Terminal 11q Duplications Cause a Bleeding Tendency due to Platelet Dysfunction That Is Similar to 11q Deletions Causing Jacobsen Syndrome

    by Elise J. Huisman, Virgil A. S. H. Dalm, Marieke Joosten, Frans J. Smiers, Leendert Porcelijn, Arjan Hoogendijk, Hans Janssen, Nicole N. van der van der Wel, Idske C. L. Kremer Hovinga, Masja de Haas, et al.

    Introduction: Jacobsen syndrome, resulting from a terminal deletion of chromosome 11 (11q), may lead to an increased bleeding tendency due to low platelet counts or platelet dysfunction. Currently, information on bleeding tendency and platelet function in patients with nonterminal 11q‐aberrations such as larger deletions, interstitial 11q‐deletions, or 11q‐duplications is lacking.Methods: We investigated the bleeding symptoms in relation to platelet numbers and function in 14 patients: 10 patients with a terminal 11q‐deletion, one terminal 11q‐duplication, two interstitial 11q‐deletions, and one with an interstitial 11q‐duplication.Results: Twelve patients reported bleeding complications (12/14, 86%), most frequently perioperative bleeding (21%), hematomas (17%), epistaxis (13%), prolonged bleeding, and severe bruising (11%) and heavy menstrual bleeding in 4/5 postmenarcheal women (80%). Seven (50%) had platelet counts below normal values (median 62 × 109/L). Strikingly, the seven patients with a normal platelet count reported more frequent perioperative bleeding complications, as well as atypical bleeding such as intramuscular hematoma after injection than the group with low platelet counts. Platelet dysfunction was detected in all (100%) patients by light transmission aggregometry (LTA). Mass‐spectrometry (MS) analysis showed an overrepresentation of NUBP2 and ATP5S, both involved in mitochondrial ATP synthesis. Electron microscopy (EM) confirmed abnormal granules in some.Conclusions: We demonstrated increased bleeding tendency due to platelet disorders in the majority of patients with terminal 11q‐deletions but also in nonterminal 11q‐aberrations. This is confirmed by abnormal platelet function tests and MS. We therefore recommend screening of patients with all forms of 11q‐disorders and, when indicated, preventive preoperative measurements and counseling for heavy menstrual bleeding in females.

  • Open Access

    Novel STAT3 Y360C Gain-of-function Variant Underlies Immune Dysregulation and Aberrancy in Mitochondrial Dynamics

    by Kornvalee Meesilpavikkai, Kasiphak Kaikaew, Zijun Zhou, Virgil A.S.H. Dalm, Fabian M.P. Kaiser, Christopher Schliehe, Sigrid M.A. Swagemakers, Peter J. van der Spek, Benjamin Schrijver, Pamela Vasic, et al.

    Meesilpavikkai K, et al. Immune Netw. 2025 Apr;25(2):e18. https://doi.org/10.4110/in.2025.25.e18


  • Open Access

    Exploring lymphocyte subsets in COVID-19 patients: insights from a tertiary academic medical center with a high proportion of patients on immunosuppression

    by Katrijn Daenen, Samantha van Hooijdonk, Kirby Tong-Minh, Willem A. Dik, Petrus M. van Hagen, Jilske A. Huijben, Diederik Gommers, Eric C. M. van Gorp, Henrik Endeman, Virgil A. S. H. Dalm

    Introduction: Severe COVID-19 is associated with reduced absolute lymphocyte counts, suggesting that lymphocyte subsets may serve as predictors of clinical outcomes in affected patients. Early identification of patients at risk for severe disease is crucial for optimizing care, accurately informing patients and their families, guiding therapeutic interventions, and improving patient flow in the ED. Given that immunosuppressive drugs significantly impact lymphocyte profiles, we aimed to determine the association between prior use of immunosuppressive drugs, lymphocyte subsets, and COVID-19 severity in our population with a high prevalence of immunosuppression.Methods: In 2021, suspected COVID-19 patients were included in the ED. Lymphocyte subsets were determined in peripheral blood within 24 hours after presentation and comparative analyses was performed between SARS-CoV-2 negative and positive patients, mild versus severe disease and patients with and without prior immunosuppressive drug use. Mild cases were patients discharged home or admitted to a general ward, severe cases were patients with COVID-19-related mortality or necessitating ICU admission. Logistic regression analysis was performed to assess the association between lymphocyte subsets and COVID-19 severity, and between prior immunosuppressive drug use and COVID-19 severity.Results: Twenty-five SARS-CoV-2 negative and 77 SARS-CoV-2 positive patients were included, whereof 57 (74%) had mild and 20 (26%) severe COVID-19. No significant differences were observed in the absolute counts of CD3+, CD4+, and CD8+ T-lymphocytes, B-lymphocytes, and NK-cells between SARS-CoV-2 negative and positive patients or between mild and severe cases. The 36 patients with prior use of immunosuppressive drugs had significantly lower CD4+ T-lymphocytes (p<0.01). Prior use of immunosuppressive drugs was not associated with COVID-19 severity (adjusted OR 1.074, 0.355-3.194).Conclusion: Lymphocyte subsets were not significantly different between SARS-CoV-2 negative and positive patients and between mild versus severe cases. Neither lymphocyte subsets nor prior immunosuppressive drug use were associated with COVID-19 severity.


  • Open Access

    Polysaccharide, Conjugate, and mRNA-based Vaccines are Immunogenic in Patients with Netherton Syndrome

    by Anouk E. M. Nouwen, Luca M. Zaeck, Renske Schappin, Daryl Geers, Lennert Gommers, Susanne Bogers, Willem A. Dik, Suzanne G. M. A. Pasmans, Corine H. GeurtsvanKessel, Rory D. de Vries, et al.

    Background: Netherton syndrome (NS) is a rare, severe genetic skin disorder, currently classified as an inborn error of immunity (IEI) due to previously reported immune dysregulation. We recently reported the results of an immunological evaluation showing no evidence for a relevant B- and/or T-cell mediated immunodeficiency, but immune responses after vaccination were not evaluated in that study. Therefore, we evaluated immune responses to three vaccine platforms in adult NS patients to further investigate the presence of a clinically relevant B- and/or T-cell immunodeficiency. Methods: Vaccination responses in eight adult NS patients were assessed in a cross-sectional study performed between January and August 2022. Clinical patient data were retrospectively retrieved from electronic patient files. Immune responses to a polysaccharide Streptococcus pneumoniae vaccine (PPV23) and conjugate Haemophilus influenzae type b vaccine (ActHiB) were measured. SARS-CoV-2-specific (functional) antibody and T-cell responses following booster vaccination with an mRNA-based COVID-19 vaccine were compared to controls. Results: None of the included patients suffered from recurrent and/or severe infections that could be attributed to a B- and/or T-cell immunodeficiency. ActHiB induced immune responses were normal in 7/7 NS patients. PPV23 induced responses were absent in 1/7, diminished in 2/7, and normal in 4/7 patients. Levels of SARS-CoV-2-specific binding and neutralizing antibodies after mRNA-based COVID-19 booster vaccination in NS patients were comparable to controls. SARS-CoV-2-specific CD4 + T-cell responses were detectable in all NS patients. In contrast, SARS-CoV-2-specific CD8 + T-cell responses were detectable in only 2/6 NS patients. T-cell responses to a positive control antigen pool were comparable to controls. Conclusions: Vaccine-induced immune responses were detectable after polysaccharide, conjugate and mRNA-based vaccination in our cohort of NS patients. A spectrum of responsiveness to vaccine challenges was found, with the ranges of vaccine responses overlapping those demonstrated in healthy control populations.


  • Open Access

    Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program

    by Leanne P. M. van Leeuwen, Marloes Grobben, Corine H. GeurtsvanKessel, Pauline M. Ellerbroek, Godelieve J. de Bree, Judith Potjewijd, Abraham Rutgers, Hetty Jolink, Frank L. van de Veerdonk, Marit J. van Gils, et al.

    Purpose: Previous studies have demonstrated that the majority of patients with an inborn error of immunity (IEI) develop a spike (S)-specific IgG antibody and T-cell response after two doses of the mRNA-1273 COVID-19 vaccine, but little is known about the response to a booster vaccination. We studied the immune responses 8 weeks after booster vaccination with mRNA-based COVID-19 vaccines in 171 IEI patients. Moreover, we evaluated the clinical outcomes in these patients one year after the start of the Dutch COVID-19 vaccination campaign.Methods: This study was embedded in a large prospective multicenter study investigating the immunogenicity of COVID-19 mRNA-based vaccines in IEI (VACOPID study). Blood samples were taken from 244 participants 8 weeks after booster vaccination. These participants included 171 IEI patients (X-linked agammaglobulinemia (XLA;N=11), combined immunodeficiency (CID;N=4), common variable immunodeficiency (CVID;N=45), isolated or undefined antibody deficiencies (N=108) and phagocyte defects (N=3)) and 73 controls. SARS-CoV-2-specific IgG titers, neutralizing antibodies, and T-cell responses were evaluated. One year after the start of the COVID-19 vaccination program, 334 study participants (239 IEI patients and 95 controls) completed a questionnaire to supplement their clinical data focusing on SARS-CoV-2 infections.Results: After booster vaccination, S-specific IgG titers increased in all COVID-19 naive IEI cohorts and controls, when compared to titers at 6 months after the priming regimen. The fold-increases did not differ between controls and IEI cohorts. SARS-CoV-2-specific T-cell responses also increased equally in all cohorts after booster vaccination compared to 6 months after the priming regimen. Most SARS-CoV-2 infections during the study period occurred in the period when the Omicron variant had become dominant. The clinical course of these infections was mild, although IEI patients experienced more frequent fever and dyspnea compared to controls and their symptoms persisted longer.Conclusion: Our study demonstrates that mRNA-based booster vaccination induces robust recall of memory B-cell and T-cell responses in most IEI patients. One-year clinical follow-up demonstrated that SARS-CoV-2 infections in IEI patients were mild. Given our results, we support booster campaigns with newer variant-specific COVID-19 booster vaccines to IEI patients with milder phenotypes.